SEARCH

SEARCH BY CITATION

References

  • 1
    Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical, haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication. Br Med J 1973; 4: 576 81.
  • 2
    Hughson WG & Mann Garrod JI. Intermittent claudication: prevalence and risk factors. Br Med J 1978; i: 1379 81.
  • 3
    Stuart J, George AJ, Davies AJ, Aukland A, Hurlow RA. Haematological stress syndrome in atherosclerosis. J Clin Pathol 1981; 34: 464 7.
  • 4
    Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen and activation of coagulation and leucocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915 20.
  • 5
    Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338 42.
  • 6
    Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738 42.
  • 7
    Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992; 2: 457 66.
  • 8
    Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, Mac Gregor IR, Dawes J. Cross-linked fibrin degration products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84 6.
  • 9
    Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM, Powell JT. Influence of smoking and plasma factors on patency of femoropoliteal vein grafts. Br Med J 1989; 299: 643 6.
  • 10
    Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Hemostasis 1992; 68: 261 3.
  • 11
    Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis 1996; 120: 25 35.
  • 12
    Ernst E & Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Int Med 1993; 118: 956 63.
  • 13
    Singer A & Rob C. The fate of the claudicator. Br Med J 1960; ii: 633 6.
  • 14
    Dormandy JA & Murray GD. The fate of the claudicant – a prospective study of 1969 claudicants. Eur J Vasc Surg 1991; 5: 131 3.
  • 15
    European Working Group on Critical Leg Ischaemia Second European Consensus document on chronic critical leg ischaemia. Circulation 1991; 84 (supp IV): 1 26.
  • 16
    Wolfe JHN. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986; 73: 321.
  • 17
    Lepantalo M & Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg 1996; 11: 153 7.
  • 18
    The i.c.a.i. Group (gruppo di sudio delli'ischemia cronica critica degli arti inferiori). A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. Eur J Vasc Endovasc Surg 1996; 11: 112 20.
  • 19
    Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res 1988; 52: 453 68.
  • 20
    Kiekara O, Riekkinen H, Soimakallio S, Lansimies E. Correlation of angiographically determined reduction of vascular lumen with lower-limb systolic pressures. Acta Chir Scand 1985; 151: 437 40.
  • 21
    Winsor T. Influence of arterial disease on the systolic blood gradients of the extremities. Am J Med Sci 1950; 220: 117 26.
  • 22
    Rumeau M & Pourrat JP. Prognostic value of fibrinogen level in geriatric patients. Lancet 1981; i: 951.
  • 23
    Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996; 16: 351 6.
  • 24
    Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet 1986; ii: 533 7.
  • 25
    Rosengren A & Wilhelmsem L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and non smokers. The study of men born in 1933. J Int Med 1996; 239: 499 507.
  • 26
    ECAT Angina Pectoris Study GroupECAT angina pectoris study: baseline associations of hemostatic factors with extent of coronary atherosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8 17.
  • 27
    Mc Kenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 2–3: 119 28.
  • 28
    Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly. The Cardiovascular Health Study. Am J Epidemiol 1996; 143: 665 76.
  • 29
    Sharp DS, Abbott RD, Burchfiel CM, Rodriguez BL, Tracy RP, Yano K, Curb DJ. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 1996; 16: 262 8.
  • 30
    Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, Psaty BM, Savage PJ. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 yrs. Results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2: 509 19.
  • 31
    Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients: a matched case control study. Atherosclerosis 1996; 125: 91 101.
  • 32
    Ernst E. Fibrinogen as a cardiovascular risk factor. Interrelationship with infections and inflammation. Eur Heart J 1993; 14 (Suppl. K): 82 7.
  • 33
    Lowe G. The biochemistry of critical limb ischaemia. Crit Ischaem 1991; 1: 11 23.
  • 34
    Woodburn KR, Rumley A, Lowe GDO, Pollock JG. Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia. Eur J Vasc Endovasc Surg 1995; 10: 272 8.
  • 35
    Erslev AJ. Anemia of chronic disease. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th edn. New York, NY. McGraw-Hill, 1995; 518 24.
  • 36
    Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183 6.
  • 37
    Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events. The Edinburgh Artery study. Br J Haematol 1997; 96: 168 73.
  • 38
    Lowe GDO. Blood rheology in arterial disease. Clin Sci 1986; 71: 137 46.
  • 39
    Ceriello A, Pirisi M, Giacomello R, Stel G, Faletti E, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994; 71: 593 5.